Evommune (EVMN) Free Cash Flow (2024 - 2026)
Evommune (EVMN) posted quarterly Free Cash Flow of -$27.5 million for Q1 2026, down 15.24% year-over-year from -$32.5 million in Q1 2025, and down 65.88% quarter-over-quarter from -$16.6 million in Q4 2025.
Powered by 
Analysis
Evommune (EVMN) Free Cash Flow (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Free Cash Flow for 3 consecutive years, with -$27.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 15.24% year-over-year to -$27.5 million; the TTM figure through Mar 2026 stood at -$68.0 million (changed N/A YoY), while the FY2025 annual figure was -$76.5 million, down 31.21% from the prior year.
- Free Cash Flow fell to -$27.5 million in Q1 2026 per EVMN's latest filing, from -$16.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$16.6 million in Q4 2025 and bottomed at -$27.5 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$21.6 million across 3 years, with a median of -$21.2 million in 2024.
- Annual changes were most pronounced in 2025 — Free Cash Flow rose 10.31% — and 2026, when it fell 15.24%.
- Evommune's Free Cash Flow stood at -$18.5 million in 2024, then climbed by 10.31% to -$16.6 million in 2025, then slumped by 65.88% to -$27.5 million in 2026.
- Business Quant data shows EVMN's Free Cash Flow at -$27.5 million in Q1 2026, -$16.6 million in Q4 2025, and -$23.9 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Evommune | 446.46 Mn | 245.66 Mn | - | -20.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.50 Mn |
| Mar 31, 2026 | -27.59 Mn |
| Dec 31, 2025 | -16.80 Mn |
| Sep 30, 2025 | -9.77 Mn |
| Jun 30, 2025 | -26.21 Mn |
| Mar 31, 2025 | -23.90 Mn |
| Dec 31, 2024 | -18.51 Mn |